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Cystic fibrosis (CF) is a monogenic disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene,
with lung and liver manifestations. Because of pitfalls of gene therapy, novel approaches for reconstitution of the airway epithelium
and CFTR expression should be explored. In the present study, human amniotic mesenchymal stem cells (hAMSCs) were isolated
from term placentas and characterized for expression of phenotypic and pluripotency markers, and for diﬀerentiation potential
towards mesoderm (osteogenic and adipogenic) lineages. Moreover, hAMSCs were induced to diﬀerentiate into hepatocyte-like
cells, as demonstrated by mixed function oxidase activity and expression of albumin, alpha1-antitrypsin, and CK19. We also
investigated the CFTR expression in hAMSCs upon isolation and in coculture with CF airway epithelial cells. Freshly isolated
hAMSCs displayed low levels of CFTR mRNA, which even decreased with culture passages. Following staining with the vital
dye CM-DiI, hAMSCs were mixed with CFBE41o- respiratory epithelial cells and seeded onto permeable filters. Flow cytometry
demonstrated that 33–50% of hAMSCs acquired a detectable CFTR expression on the apical membrane, a result confirmed by
confocal microscopy. Our data show that amniotic MSCs have the potential to diﬀerentiate into epithelial cells of organs relevant
in CF pathogenesis and may contribute to partial correction of the CF phenotype.
1. Introduction
Human placenta may represent a fruitful reserve of stem cells
for regenerative medicine. Amniotic epithelial cells (hAECs)
and amniotic mesenchymal stromal cells (hAMSCs) are
known to have unique characteristics, such as derivation
from early embryological development, low level expression
of major histocompatibility complex antigens, and a less-
restricted diﬀerentiation potential [1]. In culture, hAECs
and hAMSCs can diﬀerentiate toward “classic” mesodermal
lineages (osteogenic, chondrogenic, and adipogenic), as well
as toward cell types of all three germ layers-ectoderm, meso-
derm, and endoderm (reviewed in [2, 3]). Because the amni-
otic membrane is discarded after delivery, it is easy to obtain
without harming mothers or babies and would thereby over-
come the ethical issues associated with the use of embryonic
stem cells. Based on these considerations, human amniotic
membrane/amnion-derived cells are considered to be a use-
ful biological material and also a novel cell source for cell
transplantation. The availability of hAECs and hAMSCs and
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the lack of ethical concerns for this source of stem cells are
considered advantageous for their widespread use and accep-
tance.
Cystic fibrosis (CF) is a lethal autosomal recessive disor-
der due to mutations in the CF transmembrane conductance
regulator (CFTR) gene, a cAMP-dependent chloride channel
expressed on the apical side of epithelial cells [4]. Although
CF involves many organs with secretory/absorptive proper-
ties, including the liver, the main cause of morbidity and
mortality is a chronic inflammatory lung disease. Because of
its monogenic nature, and since the lung is easily accessible,
CF has been a target disease for gene-based therapeutic inter-
vention; however, this approach has given unsatisfied results
in terms of eﬃciency of gene delivery to the lung and of eﬃ-
cacy outcomes [5]. This partial success was due to the inef-
ficiency of passing the mucus barrier overlying the epithelial
cells and to the immune response against the gene therapy
vectors [6]. Cell therapy could be a more eﬀective treatment
because allogenic normal cells and autologous engineered
cells express CFTR gene. Bone marrow-derived stem cells
have been the first source evaluated for homing to the lung
and curative potential, but the in vivo eﬃciency of bone mar-
row stem cells to diﬀerentiate in airways epithelium is very
low (0.01–0.025%) [7], as also demonstrated by diﬀerent
studies in CF mice [8, 9].
Recently, new cell sources for CF treatment have been
characterized; MSCs from cord blood [10] and amniotic
fluid stem cells [11] can diﬀerentiate in vitro and in vivo in
airway epithelium. Stemming from these results on MSCs,
and based on the demonstrated high plasticity of amniotic-
derived stem cells, after an extensive characterization of
the expression of phenotypic and pluripotency markers by
hAMSCs and their diﬀerentiative potential, we preliminarily
evaluated their usefulness in CF by in vitro experiments using
cocultures of hAMSCs and CF-respiratory epithelial cells.
2. Materials and Methods
2.1. Isolation and Culture of Human Amniotic Mesenchymal
Stromal Cells. Human amniotic mesenchymal stromal cells
(hAMSCs) were isolated from term placentas (n = 3) which
would normally be discarded after delivery. Tissues were
obtained under appropriate Ethical Committee approval and
signed informed consent. All infectious pathogen-positive
deliveries including those involving HBV, HCV, and HIV,
as well as cases of prediagnosed genetic abnormalities, were
excluded. Placenta samples were procured immediately after
delivery and processed under sterile conditions. After peeling
from the placenta and washing with calcium- and magnesi-
um-free HBSS (CMF-HBSS, Lonza, Treviglio, Italy) supple-
mented with 0.5 mM EGTA (Sigma, Milan, Italy), amnion
membranes were processed to remove epithelial cells as pre-
viously reported [12]. Once epithelial cells were removed,
the amniotic membranes were digested in order to collect
hAMSCs [13]. Briefly, amniotic membranes were washed
three times with cold HBSS, cut into pieces, and transferred
into 50-mL centrifuge tubes, containing about 30–40 mL of
digestion solution composed by EMEM (Lonza) supple-
mented with 25 mM HEPES buﬀer without L-glutamine
(Lonza), 1 mg/mL collagenase type IV, and 25 μg/mL DNase I
(both from Sigma, Milan, Italy). Membranes were incubated
on a rotator between 45 min to 1.5 h, depending on tissue
thickness, at 37◦C. After blocking the enzymatic reaction
with cold HBSS, cell suspensions were centrifuged 2 times for
5 min at 200×g, 4◦C and counted using a Bu¨rker chamber.
After isolation, DNA was obtained from hAMSCs and
hAECs by phenol/chlorophorm extraction. Purified DNA
was investigated for most frequent mutations in CFTR gene
using a commercial kit (Inno-Lipa CFTR19, Inno-Lipa
CFTR17+TnUpdate, Inno-Lipa CFTR-Italian Regional-
Innogenetics, Ghent, Belgium).
hAMSCs were plated at a density of 1× 105 cells per cm2
in standard culture medium composed by DMEM (Lonza)
supplemented with 1% sodium pyruvate, 10% (v/v) heat-
inactivated fetal bovine serum (FBS), 1% nonessential amino
acid, 55 μM β-mercaptoethanol (all by Invitrogen, Milan,
Italy), 1% L-glutamine, 1% antibiotics solution (both by
Cellgro, Manassas, VA, USA), and 10 ng/mL epidermal
growth factor (EGF, Sigma), according to the previously
reported protocol [13]. Medium was replaced 2 h after plat-
ing in order to remove unattached contaminating epithelial
cells and then every 2 days.
Every time cells reached 80% of confluence, cells were
detached with trypsin-EDTA (Invitrogen), washed, counted
with a Bu¨rker chamber, and replated in a new plastic flask at
a density of 1 × 105 cells per cm2 in order to calculate their
growth curve. Doubling time was calculated inserting times
and cell counts on the website http://www.doubling-time
.com/compute.php.
2.2. Characterization of hAMSCs
2.2.1. Flow Cytometry. Flow cytometry analyses of hAMSCs
were performed immediately after dissociation and at second
culture passage as previously described [14]. Briefly, cells
were detached from culture flask using trypsin and, after
washing, were incubated with 4% normal mouse serum/PBS/
NaN3 for 20 minutes at 4◦C in order to block nonspecific
sites on cell membrane. Cells were then stained in the dark at
4◦C for 20 minutes with 7-amino actinomycin-D (7AAD) to
discriminate viable cells from fragments and dead cells and
with the following monoclonal antibodies (moabs): against
CD13, CD29, CD31, CD34, CD44, CD45, CD49f, CD73,
CD90, CD105, CD146, CD166, EpCAM, SSEA4 (all from
Becton Dickinson Biosciences, BD, Franklin Lakes, NJ, USA),
and CD133-1 (Miltenyi Biotech, Bergisch Gladbach, Ger-
many). Moabs were conjugated with fluorescein isothiocya-
nate (FITC) or phycoerythrin (PE) or PE-Cyanin 7 (PE-Cy7)
or allophycocyanin (APC) or APC-Cyanin 7 (APC-Cy7).
For internal labelling, cells were fixed at room tempera-
ture with 4% paraformaldehyde (PFA) for 10 min and per-
meated with 100% ethanol for 2 min after washing with PBS.
Cells were incubated with 10% FBS to block nonspecific
binding, followed by primary antibodies against Oct-4 and
Nanog (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for
1 h; secondary PE-conjugated antibody (Invitrogen) was ap-
plied for 30 min. The fluorescence threshold between nega-
tive and positive cells was set on the basis of the reactivity of
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appropriate nonspecific fluorochrome-conjugated isotypic
controls. At least, 106 cells were finally analysed using a
FACSCanto II equipped with FACSDiva software (BD).
2.2.2. Immunofluorescence Microscopy of Cultured Cells. Plat-
ed cells were stained as reported elsewhere [14]. Fixed (4%
PFA or 70% ethanol for 30 min) and permeabilized (HEPES-
Triton X-100 buﬀer 0.25% in PBS for 20 min) cells were in-
cubated with a blocking buﬀer containing 0.5 M NaCl,
20 mM NaHPO4, 0.1% Triton X-100, and 30% horse and
goat serum for 30 min (all reagents were from Sigma) and
then immunostained with the following primary moabs:
anti-EpCAM, cytokeratin (CK)18, alpha-fetoprotein (Sigma),
CK19 (Novocastra, Newcastle, UK), albumin (DakoCyto-
mation, Milan, Italy), CK7, CD49f, CD29, S100A4, CD90,
CD31, CD146, zonula occludens-1 (ZO-1), fibronectin, al-
pha1-antitrypsin, E-cadherin, and beta-catenin (BD) for 2 h.
After washing, cells were incubated with the appropriate sec-
ondary FITC or Texas Red-conjugated antibodies (BD) for
1 h in the dark. Nuclei were counterstained with 4′,6-diami-
dino-2-phenylindole (DAPI, Sigma) for 5 min in the dark.
Images were taken using a Leica Microsystems DM IRE 2
microscope and analysed with the FW4000I software (Leica
Microsystems, Milan, Italy).
2.2.3. Reverse-Transcriptase (RT)-Polymerase Chain Reaction
(PCR). CFTR mRNA expression was investigated by semi-
quantitative RT-PCR. Total RNA was isolated from freshly
isolated and cultured cells with TRIzol Reagent (Invitro-
gen), according to the manufacturer’s protocol. One μg of
RNA was reverse transcribed into first strand cDNA with
the High-Capacity cDNA Reverse Transcription kit (Applied
Biosystems) using random primers following manufacturer’s
instructions. In order to analyze the expression of CFTR
gene, 100 ng of cDNA was used in a final volume of 25 μL
with 200 nM dNTP, 10 pM of each outer primer (Table 1),
0.3 U Taq-DNA-polymerase, reaction buﬀer, and MgCl2 (In-
vitrogen). A second nested PCR was performed using inner
primers (Table 1). Cycling conditions consisted of 95◦C for
30 seconds, annealing at 60◦C for 1 min and elongation at
72◦C for 2 min. Cycle numbers consisted of 35 cycles. cDNA
from nasal brushing from healthy control was used as posi-
tive control for CFTR analysis; no reverse-transcribed sample
was used as negative control.
In parallel, β-actin was used as house-keeping gene
(Table 1). PCR products were evaluated on 1.5% agarose gel
electrophoresis.
2.3. Diﬀerentiation of hAMSCs Towards Diﬀerent Lineages
2.3.1. Adipogenic and Osteogenic Diﬀerentiation. To induce
adipogenic and osteogenic diﬀerentiation, cells at passages 1–
3 were harvested and plated on tissue culture dishes (BD) at
a density of 4×103 cells per cm2. Cells were then treated with
either adipogenic or osteogenic diﬀerentiation media (Lonz-
a) for three weeks. The adipogenic protocol consisted of 4
rounds of adipogenic induction medium for 2 days followed
by adipogenic maintenance medium for 3 days. The presence
of adipose elements in induced cultures was determined by
Oil-Red-O (Sigma) staining as follow: cells were washed in
PBS, then fixed in 10% formalin for 1 h, washed in isopro-
panol 60%, and air dried. Cells were then incubated with Oil-
Red-O staining solution for 10 min, then washed several
times in PBS, and observed with an inverted microscope
Eclipse TS100 (Nikon, Tokyo, Japan) equipped with a DS-FI1
CCD camera (Nikon).
In order to induce osteogenesis, cells were treated with
osteogenic medium for 3 weeks with medium changes 3
times a week. The presence of calcium deposits in induced
cultures was determined by Alizarin Red (Sigma) staining
as follow: cells were fixed in 10% formalin for 1 h, then
washed in deionized water, and incubated for 30 min at room
temperature with Alizarin Red 2% in water at pH 4.2. The
cells were finally washed several times to remove the excess
of staining and analyzed as described above.
2.3.2. Hepatocyte Diﬀerentiation. A simple protocol [15] was
used for hepatic diﬀerentiation of hAMSCs; cells were plated
on type 1 collagen-coated culture dishes in DMEM supple-
mented with 10% FBS, 1% nonessential aminoacids, 1% L-
glutamine, beta-mercaptoethanol, and 10 ng/mL of EGF for
8 days and then with IMDM with the same compounds plus
10−7 M dexamethasone (Sigma) for 6 days. One of the func-
tions in cultured hepatocytes is that of the cytochrome P450-
dependent mixed function oxidases (MFOs). Diethoxy (5,6)
chloromethylfluorescein (Invitrogen) is a probe suitable for
use as an in situ stain for MFO activity since this colorless
molecule is metabolized in a fluorescent green compound
retained in the cells [16]. Five mg of probe was eluted in
1143 μL DMSO (stock solution 10 mmol). Test medium was
prepared as follow: 987 μL of RPMI, 12 μL HEPES 1 M
(12 mmol final), and 1 μL probe 10 mmol (10 μmol final).
Control medium was prepared as follow: 987 μL RPMI, 12 μL
HEPES 1 M (12 mmol final), and 1 μL DMSO. The cells were
washed in PBS and incubated with the test (or control) med-
ium for 2 h at 37◦C in a CO2 incubator. Cells were analyzed
using a Leica Microsystems DM IRE 2 microscope.
After diﬀerentiation for 21 days (8 days in DMEM sup-
plemented as above +13 days in IMDM supplemented with
dexamethasone), cells were stained by means of immunoflu-
orescence as reported above in order to verify the expression
of epithelial markers.
2.4. hAMSC Labelling. Passage two hAMSCs were labeled
with chloromethylbenzamido (CellTracker CM-DiI) [17].
Stock solutions of CM-DiI were prepared in dimethylsulfox-
ide (DMSO) at 1 ng/μL. Immediately before labelling, the
stock solution was diluted up to a final concentration of
0.005 ng/μL in DMEM without phenol red. Cells grown at
confluence in a T25 flask were washed with phosphate-buﬀ-
ered saline (PBS) and then incubated with the dye working
solution for 30 min at 37◦C. After labelling, cells are washed
twice with PBS, then incubated at 37◦C 5% CO2 for at least
24 h in the presence of fresh medium.
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Table 1: Primer sequences for CFTR RT-PCR analysis.
Gene Forward primer Reverse primer Product length (bp)
CFTR
Outer primers CGAGAGACCATGCAGAGGTC GCTCCAAGAGAGTCATACCA 1108
Inner primers CGAGAGACCATGCAGAGGTC TGTACTGCTTTGGTGACTTCCCC 301
β-actin CAACTGGGACGACATGGA ACGTCACACTTCATGATGGA 610
2.5. Cultures of Airway Epithelial Cells. 16HBE14o- and
CFBE41o- are human epithelial bronchial cell lines, wild type
and homozygous for the F508del allele (F508del/F508del),
respectively, a generous gift of Professor D. Gruenert (Uni-
versity of California at San Francisco, USA). Epithelial cells
were grown in MEM, 10% FBS, 100 U/mL penicillin, and
100 U/mL streptomycin, alone or in Coculture with hAM-
SCs.
2.6. Coculture of hAMSCs with CFBE41o- Cells. Labelled
hAMSCs were mixed with CFBE41o- cells at diﬀerent ratios
(1 : 5, 1 : 10, 1 : 15, and 1 : 20) and, in order to obtain polar-
ized cocultures, cells were seeded on 6.5-mm diameter Snap-
well, 0.4-μm pore size (Corning, Acton, MA, USA) at 1×105
per filter coated with a solution of 10 μg/mL fibronectin (BD
Biosciences, CA, USA), 100 μg/mL albumin from bovine
serum (Sigma-Aldrich, Milan, Italy), and 30 μg/mL bovine
collagen type I (BD) dissolved in MEM. As controls, hAMSCs
and CFBE41o- were seeded at 2.5×104 and 1×105 per filter,
respectively. Cocultures were maintained at 37◦C 5% CO2 for
at least 6–8 days.
Separate cocultures were obtained by seeding hAMSCs
onto the filter and CFBE41o- cells onto the bottom of the
lower chamber. To obtain 1 : 5 and 1 : 10 ratios, hAMSCs were
seeded at 2× 104 and 1× 104 and CFBE41o- cells at 8× 104
and 9×104, respectively. As controls, hAMSCs were seeded at
1×105 per filter. Medium was changed daily in each chamber
for 5 days, and cultures were analyzed at day 6.
2.7. CFTR Cytofluorimetric Assay. Cells were detached with
trypsin-EDTA treatment and fixed in PBS containing 2%
PFA for 5 min. After centrifugation at 250×g, the resulting
pellets were washed and resuspended in PBS. The cells
were then incubated with CFTR antibody MAB25031 mouse
IgG2a (R&D Systems, Minneapolis, MN, USA) used at 1 : 20
dilution for 1 h at 4◦C. After washing in PBS, the cells were
incubated with the FITC-conjugated secondary antibody
(anti-mouse used at 1 : 100; Sigma) for 1 h at 4◦C, followed
by two washes in PBS, and analyzed. As a background con-
trol, cocultures were incubated with secondary antibody
only, and the resulting fluorescence was subtracted from the
analyzed samples incubated both with primary and second-
ary antibodies. Data were collected using a Coulter Epix XL
flow cytometer (Beckman Coulter, Fullerton, CA, USA) and
analyzed with WinMDI 2.9 (http://www.cyto.purdue.edu/
flowcyt/software/Winmdi.htm). Ten thousand cells were ex-
amined in each experiment. Since physical parameters (for-
ward scatter and side scatter) did not allow us to distinguish
hAMSCs from CFBE41o- cells, specific expression of CFTR
on hAMSCs was detected in the CM-DiI-labelled cells. Anal-
yses were performed by plotting the FLH-1 channel (525 nm)
against the FLH-2 channel (575 nm), identifying the CFTR-
specific green signal and the red-labelled hAMSCs, respec-
tively. The vitality was evaluated by trypan blue exclusion as-
say and resulted to be >98%.
2.8. Confocal Analysis of CFTR Protein. Polarized cells were
washed three times with PBS and incubated in PBS, 2% BSA
for 30 min on ice. Cells were incubated with CFTR anti-
body MAB25031 diluted 1 : 20 in PBS containing 0.2% BSA
for 1 h on ice. Cells were rinsed three times with PBS and
incubated with the FITC-conjugated secondary antibody dil-
uted 1 : 100 in PBS added with 0.2% BSA for 30 min on ice.
After two washes in PBS, cells were fixed in 3% PFA and 2%
sucrose for 10 min. After three washes in PBS, filters were
excised and placed side up on a glass slide and overlaid with
a drop of Mowiol (Calbiochem, San Diego, CA, USA) follow-
ed by a coverslip. Cells were analyzed using a Nikon TE2000
microscope coupled to a Radiance 2100 confocal dual-laser
scanning microscopy system (Bio-Rad, Segrate, Italy). Spec-
imens were viewed through a 60x oil immersion objective.
Digital images were processed using the program Laser Sharp
2000 (Bio-Rad).
2.9. Statistical Analysis. Statistical significance of diﬀerences
was evaluated by a two-tailed unpaired Student’s t-test. Data
were analyzed using Prism 4 (GraphPad Software, Inc., La
Jolla, CA, USA). P values of less than 0.05 were considered
significant.
3. Results
3.1. Isolation and Characterization of hAMSCs from Human
Amnion. At least 33 × 106 hAMSCs (range 26–160 × 106)
were recovered in each isolation (n = 3) with a viability of
85–90%. Inno-lipa screening revealed the absence of most
frequent mutation of CFTR (86% of detection rate) in
hAMSCs used in this study. After plastic adhesion, hAMSCs
were characterized by a fibroblastic morphology very similar
to that described for mesenchymal cells isolated from bone
marrow (Figures 1(a) and 1(b)) and could be kept in culture
until passages 5–10. Proliferation slowed beyond passage
two. In the exponential growth phase, approximately two cell
doublings were observed over 15 days, giving these cells an
average doubling time of 18.03 days calculated over 28 days
of culture. An example of a growth curve for hAMSCs is
presented in Figure 1(c).
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Figure 1: hAMSCs morphology and growth. Cell morphology at passage one (a) and passage three (b), original magnification 10x. Growth
kinetics of hAMSCs in culture (c).
3.2. Flow Cytometry and Immunofluorescence Analysis. hAM-
SCs showed an immunophenotypic profile very similar to
that of mesenchymal stem cells derived from bone marrow;
that is, they are positive for CD29, CD44, CD73, CD90,
and CD105 and negative for the hematopoietic markers
CD34, CD133, and CD45. Freshly isolated hAMSCs showed
a low expression of epithelial markers (EpCAM and CD49f),
which decreased up to null expression after the first passage
(Table 2).
hAMSCs showed the embryonic stem cell associated sur-
face marker SSEA4 (Figure 2(f)), while very low expression
of molecular markers associated with pluripotent stem cells
(Nanog and Oct-4) by flow cytometry was observed (Figures
2(d) and 2(e)).
Fluorescence microscopy confirmed the positivity for
CD29 and CD90 and revealed the expression of other mesen-
chymal markers such as fibronectin and vimentin (Figure 3).
hAMSCs were almost negative for ZO-1, a marker of tight
junctions and cytokeratin (CK) 7, while stained positive for
CK18.
3.3. Cell Diﬀerentiation Ability. To determine whether hAM-
SCs could diﬀerentiate into adipocytes, cells were allowed to
grow to 70% confluence prior to induction. Morphological
changes as well as formation of lipid droplets within the cells
were noticeable starting from one week after induction and
were visualized by Oil-Red-O staining (Figure 4(b)). Cells
maintained in control medium did not show any sign of adi-
pogenic diﬀerentiation (Figure 4(a)).
To investigate the osteogenic potential of hAMSCs, cells
were cultured under appropriate condition for diﬀerentia-
tion. The presence of calcium deposits in induced cultures
was determined by Alizarin Red (Figure 4(d)). Cells main-
tained in control media did not show any change in their
morphology and no calcium deposit (Figure 4(c)).
Hepatocyte diﬀerentiation of hAMSCs was evaluated
after 14 days of induction. Cells were incubated for 2 h with
diethoxy (5,6) chloromethylfluorescein. The generation of
fluorescent products was evaluated by fluorescence micro-
scopy. Although hAMSCs were of mesenchymal origin, they
showed signs of hepatocyte diﬀerentiation (Figure 4(f)).
Cells maintained in control medium did not show any sign
of hepatocyte diﬀerentiation (Figure 4(e)).
Moreover, we performed cell immunophenotyping after
hepatocyte induction (Figure 5). After hepatocyte differenti-
ation, the number of cells expressing CK7 increased, while
some cells expressed albumin and, weakly, alpha1-antitryp-
sin. Finally, we observed also the presence of CK19- positive
cells. No alpha-fetoprotein expression was detected (not
shown).
3.4. CFTR mRNA Expression. In order to see whether
hAMSCs express CFTR mRNA, a semiquantitative RT-PCR
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Figure 2: hAMSCs pluripotent stem cells and ESC marker expression. Flow cytometry representative expression of the pluripotent and
embryonic stem cells markers in freshly isolated hAMSCs. (a) For each staining, a gate on viable cells (red) was drawn; (b) hAMSCs were
gated on the basis of morphological features; (c) cells incubated with isotypic control were used as negative controls; (d) Nanog, (e) Oct-4,
and (f) SSEA4 expression in hAMSCs.
Table 2: hAMSCs membrane marker expression.
Surface antigens
Freshly isolated Passage two
Median % Range Median % Range
CD45 2 0–4 4 3-4
CD34 0 0-1 0 0-1
CD133 0 0-1 0 0-1
CD13 80 70–89 95 89–99
CD44 81 71–90 90 89–92
CD73 90 88–91 94 88–99
CD90 79 69–89 94 89–99
CD29 76 66–86 98 95–99
CD105 49 30–66 58 40–76
CD166 83 71–95 85 71–98
CD49f 16 13–31 3 2–5
EpCAM 16 12–20 0 0-1
CD31 0 0 ND ND
CD146 0 0 ND ND
Data were expressed as median percentage and ranges of three diﬀerent experiments.
assay was carried out. CFTR was detected in hAMSCs by
RT-PCR only after nested PCR (Figure 6). The expression of
CFTR in hAMSC appeared to decrease dramatically during
culture. hAECs showed a similar expression of CFTR mRNA
when studied upon isolation (Figure 6).
3.5. CFTR Protein Expression by Flow Cytometry. hAMSCs
stained with CM-DiI (as described in Materials and Methods
section) were mixed with CFBE41o- cells at diﬀerent increas-
ing ratios (1 : 20, 1 : 15, 1 : 10, and 1 : 5) and seeded onto
semipermeable filters. In order to analyze the CFTR protein
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Figure 3: Immunofluorescence characterization of hAMSCs. Representative images of fluorescence microscopy staining. The upper left
panel (denoted as “negative”) shows cells incubated with the secondary antibody only. hAMSCs were positive for CD29, CD90, fibronectin,
vimentin, and CK 18 and negative for ZO-1 and CK 7. Nuclei were counterstained with DAPI. Original magnification 20x.
expression in hAMSC–CFBE41o- cocultures at diﬀerent ra-
tios, a flow cytometric assay was performed. This mixed pop-
ulation was analyzed after labelling with the CFTR antibody
MAB25031 in the absence of permeabilization followed by an
incubation with FITC-conjugated secondary antibody. As a
positive control, CFTR labelling was assessed in normal
human airway 16HBE14o- cells, resulting in 50 ± 5.0% of
positive cells, as previously shown [18]. CFBE41o- cells
showed less CFTR-specific labelling on the membrane (11%
of positive cells), consistent with the lack of CFTR transport
on the plasma membrane which is a characteristic of these
cells. Plasma membrane CFTR expression was detected in
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Figure 4: In vitro diﬀerentiation capability. Representative images of in vitro osteocyte (b), adipocyte (d), and hepatocyte (f) diﬀerentiation
of hAMSCs. (a), (c), and (e) represent respective negative controls (i.e., uninduced cells). Original magnification 20x.
only 6.2% of hAMSCs (Table 3). It was possible to detect an
increase of CFTR-specific signal in CM-DiI-labeled cells at all
hAMSC–CFBE41o- ratios as compared with hAMSCs cells
alone. The lower the ratio of hAMSCs : CFBE41o- the lower
the increase in CFTR-specific signal in CM-DiI-labeled cells,
these data indicating that a critical number of hAMSCs is im-
portant in order to obtain a meaningful eﬀect on CFTR
expression. Overall, these data show that a population of
hAMSCs with low CFTR expression have increased this ex-
pression upon cocultures with CF epithelial cells.
To investigate the mechanism underlying the expression
of CFTR in hAMSCs after cocultures with CFBE41o- cells, we
performed separate cocultures of hAMSCs and CFBE41o-
cells. Thus, hAMSCs were grown onto the filter whereas
CFBE41o- cells were seeded onto the bottom well. After 6
days of culture, hAMSCs were analyzed for CFTR expression
by cytofluorimetry. Results showed that, at the hAMSCs :
CFBE41o- ratios of 1 : 5 and 1 : 10, the percentages of CFTR+
hAMSCs were 10.5± 3.8 and 11.6± 5.0, respectively (n = 3).
These data, compared with those obtained in direct Cocul-
ture conditions (column “% of CFTR+ in whole CM-DiI+
population” of Table 3), indicate that a direct contact be-
tween hAMSCs and CFBE41o- is necessary to obtain a signi-
ficant increase of CFTR-specific signal in hAMSCs.
3.6. CFTR Expression and Localization by Confocal Microsco-
py. To confirm cytofluorimetric data and to analyze CFTR
expression in cell compartments, hAMSC–CFBE41o- cocul-
tures were assayed by means of confocal microscopy. In
previously published work [19], we showed that CFTR pro-
tein is expressed on the apical side of 16HBE14o-cells, while
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Figure 5: Immunophenotype of mesenchymal stem cells prior (left) and after (right) hepatocyte diﬀerentiation for 21 days. (a–f) negative
controls, (b–g) CK7, (c–h) albumin, (d–i) alpha1-antitrypsin, and (e–j) CK19. Original magnification 20x. The insert h1 represents an
enlargement of the cell highlighted by the white square.
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Figure 6: CFTR mRNA expression in hAMSCs and hAECs. CFTR on hAMSCs and hAECs upon isolation (T0) and on hAMSCs at passages
one (P1) and three (P3). Upper panels: CFTR; lower panels: β-actin. M: molecular weight markers; Ctr+: positive control (nasal brushing);
Ctr−: negative control (no RT). On the right, arrows indicate the specific band along with PCR-product length.
Table 3: Percentages of CFTR+ hMSCs labelled with CM-DiI in cocultures with CFBE41o- cells.
% of CM-DiI+ CFTR+ cells % of CFTR+ in whole CM-DiI+ population P
hAMSCs — 6.2± 2.0 —
CFBE — 11.2± 1.3 0.0006
hAMSC-CFBE 1 : 5 12.1± 2.5 50.0± 6.1 <0.0001
hAMSC-CFBE 1 : 10 7.5± 2.1 46.7± 9.3 <0.0001
hAMSC-CFBE 1 : 15 3.0± 0.4 33.2± 6.5 <0.0001
hAMSC-CFBE 1 : 20 2.2± 0.9 34.6± 8.7 <0.0001
Percentages of CM-DiI+CFTR+ cells were obtained by plotting the FLH-1 channel, identifying CFTR-specific green signal, against FLH-2 channel, identifying
red-labelled hAMSCs. Percentages of CFTR-expressing hAMSCs in whole CM-DiI+ population were obtained by dividing the double positive hAMSCs for all
CM-DiI+ cells (with and without green signal). Data are shown as the mean ± SD of five experiments. Significance is referred to CFTR+ cells in the whole
CM-DiI+ population in all conditions as compared with hMSCs alone.
CFBE41o- cells display only intracellular staining. CFTR
expression and localization was evaluated by epifluorescence
with a protocol which allows to detect only surface and not
intracellular CFTR (see Materials and Methods section), fol-
lowed by confocal microscopy analysis. As can be seen in
Figure 7, CFTR was highly expressed on the apical mem-
brane of some hAMSCs since red labelled cells showed
a green staining at membrane level (Figures 7(b)–7(d)),
whereas CFBE41o- monolayers in absence of hAMSCs
showed essentially no specific signal for CFTR expression
on the membrane (Figure 7(a)), consistent with the lack of
CFTR transport to the apical membrane in CF cells. hAMSCs
showed a very faint signal related to CFTR (Figure 7(e)).
These data confirm cytofluorimetric analysis as to the plasma
membrane expression of CFTR in labelled hMSCs which
increases when Cocultured with CF cells.
4. Discussion
Human MSCs are pluripotent stem cells initially identified in
postnatal bone marrow (BM) [20], which is the most com-
mon source used in clinical settings [21]. However, the use of
BM has some limitations, including the low frequency of
MSCs and the invasive procedure for obtaining them. More-
over, the age and disease state may aﬀect the collection of suf-
ficient healthy autologous BM for transplantation [22–24].
Finally, expansion of autologous BM cells could represent a
cumbersome and low-yield approach. In the present study,
we directed our attention on a source, the amniotic mem-
brane, which is rich in MSCs [25], is easily accessible and eth-
ically acceptable, since the term placenta is discarded after
delivery. hAMSCs have been shown to be superior in prolif-
eration and diﬀerentiation potential to BM cells [26] and to
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Figure 7: CFTR immunodetection by confocal analysis. Confocal scans are shown in the horizontal cross-section (xy) plane and vertical
cross-section (xz) plane. (a) CFBE41o- cells; (b) hAMSCs- CFBE 1 : 5 ratio; (c) hAMSCs- CFBE 1 : 10 ratio; (d) hAMSCs- CFBE 1 : 15 ratio;
(e) hAMSCs alone. The white arrows point to CM-DiI-labelled hAMSCs expressing CFTR on their membrane (green signal). Note in (d)
that hAMSCs harbour some CFTR-specific signal in discrete regions under the apical plasma membrane.
display diﬀerentiation potential towards mesoderm lineages
(osteogenic, chondrogenic, and adipogenic) similar to BM
cells [25–27]. Importantly, various studies have reported dif-
ferentiation of hAMSCs to ectoderm (neural) [27, 28], meso-
derm (skeletal muscle, cardiomyocytic, and endothelial) [26,
29–31], and endoderm (pancreatic) [32] lineages.
In the present study, we isolated and characterized
hAMSCs according to previously published protocols, that is,
by removing the epithelial cells by enzymatic digestion and
obtaining the hAMSC suspension by collagenase and DNase
treatment [26, 27, 30, 33, 34]. hAMSCs show a higher proli-
ferative potential than BM MSCs [26, 35], and, in our culture
conditions, they reached a plateau after 21 days in culture,
similarly to what has been seen in a previous study [26], while
others have observed a plateau already at day 11 [25]. hAM-
SCs displayed a fibroblastic morphology and presented sur-
face markers expressed also by BM-MSCs and cells isolated
from both the amnion and other regions of the full-term
placenta such as CD29, CD44, CD105, CD73, CD90, and
vimentin and were negative for the hematopoietic markers
CD45 and CD34 [26, 27, 35–39]. They also displayed posi-
tivity for the epithelial markers CD49f and CK18; since these
markers are lost upon culture, they could represent a small
contamination by epithelial cells, which has been described
also previously [33, 40]. This hypothesis is corroborated by
CFTR mRNA expression in hAECs upon their isolation from
the placenta (as shown in Figure 6). Interestingly, it has been
observed that adherent cells obtained from human amniotic
membranes were comprised of both round-shaped epithelial
cells and spindle-shaped fibroblast-like cells prior to the first
passage, whereas the epithelial cells were rarely detected after
the third passage [37]. In alternative, this hybrid phenotype
of hAMSCs [41] is interpreted as a sign of pluripotency and
suggests that the amnion-derived cells had not completely
diﬀerentiated into epithelial or mesenchymal cells [3]. Never-
theless, as shown here, the amniotic cells derived from term
placenta seem to remain somewhat “plastic” and maintain
the capability to diﬀerentiate and contribute to cells from dif-
ferent germ layers. Mesodermal diﬀerentiation of MSC from
various sources was widely reported in the literature and is
considered one of the principal assay to prove “stemness” of
mesenchymal cells [20, 22, 29]. Not diﬀerently from previous
papers, hAMSCs isolated in our experiments were able to
diﬀerentiate into both adipocytes and osteocytes. In recent
years, the exploitation of adipose tissue or bone marrow-de-
rived MSC for hepatocyte diﬀerentiation and liver repair was
explored by many researchers [42–44] but, to the best of our
knowledge, only one previous study has demonstrated that
hAMSCs can diﬀerentiate into hepatocyte-like cells, although
only at gene-expression level [37].
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Because amniotic cells can diﬀerentiate into diﬀerent cell
types, we examined them with antibodies directed against
well-known surface markers characteristic of embryonic
stem cells. Amniotic cells express the stage-specific embry-
onic antigen SSEA-4 [45] although the relative proportion
of SSEA-4-positive cells in initial isolates is lower than that
observed with embryonic stem cells [46]. In addition to
characteristic stem cell surface markers, amniotic cells show
very low expression of Oct-4 and Nanog, transcription fac-
tors involved in regulating ES cells’ self-renewal and diﬀer-
entiation, as it has been previously shown for freshly isolated
MSCs obtained from bone marrow, adipose tissue, and heart
[47]. Further studies are needed to understand whether these
genes are regulated during the in vitro culture conditions, so
to identify regulatory pathways that mimic in vivo activation.
CF is a potential model disease for stem cell therapy be-
cause of the persistent lung inflammation that leads to dam-
age and remodeling and can promote engraftment of stem
cells [7]. A developing potential therapeutic approach for CF
and other lung diseases has been stimulated by recent reports
demonstrating that several cell populations derived from
adult bone marrow, from amniotic fluid or from umbilical
cord blood, including MSCs, endothelial progenitor cells,
and circulating fibrocytes, can localize to the lung and ac-
quire phenotypic and functional markers of mature lung-
specific cells [10, 11, 48]. The results published by Wang et al.
[49] and Loi et al. [8] strongly suggest that the population of
BM cells relevant for repopulating the lung epithelium may
be found in the plastic adherent stromal cell compartment.
Besides the drawbacks presented by BM-MSCs discussed
above, amniotic fluid contains a heterogeneous population
of cells from fetal origin [25], whereas MSCs could not be
reliably isolated from all term umbilical cordon blood sam-
ples [10, 50–52].
In the present study, we propose human placenta as an
ethical source of MSCs for CF therapy. The first goal was to
investigate the CFTR expression in these cells. At the earliest
stages of human development, CFTR protein and function
have been detected in early blastocysts in the apical mem-
brane of trophectoderm cells, while its expression at mRNA
level has been shown in first trimester placenta (8-week ges-
tation) [53]. However, no data are available concerning its
mRNA and protein levels in specific cell types of term pla-
centa. In this study, we show that a nested RT-PCR was nec-
essary for obtaining a detectable signal from freshly isolated
hAMSCs, indicating very low levels of CFTR mRNA in these
cells. We have recently shown that also hematopoietic stem/
progenitor cells display such low levels upon purification
from the bone marrow [18]. The reason why CFTR must be
kept at low expression levels in stem/progenitor cell compart-
ments is not known at the moment. Although at this moment
we do not know whether freshly isolated hAMSCs show
CFTR expression or the specific band by RT-PCR is given by
an epithelial contamination, CFTR mRNA was barely visible
at passages one and three. Confocal microscopy confirmed
these results at the protein level. Notably, CFTR was reex-
pressed by hAMSCs upon Coculture with epithelial cells, as
demonstrated unequivocally by flow cytometry and confocal
microscope analysis. At this stage, we do not know why the
lower the hAMSCs : CFBE41o- ratios the lower the CFTR ex-
pression in hAMSCs. It can be speculated that this eﬀect
might be due to cross-talk between amniotic and epithelial
cells, for which a critical number of hAMSCs are needed. In-
deed, in other Coculture systems, developed with MSCs and
chondrocytes, it has been shown universally that the more
chondrocytes the lower the expression of extracellular matrix
genes and functional properties of engineered cartilage [54,
55].
Also, the mechanism underlying this eﬀect is to be dis-
covered yet. However, indirect cocultures data give us an in-
dication that this eﬀect is primarily due to the contact be-
tween amnion MSCs and epithelial cells, and not to factors
acting by a paracrine manner. Lung morphogenesis is an
orchestrated molecular and cellular process controlled by
cellular interactions with growth factors and morphogenic
factors [56]. Since the cellular interactions between epithelial
and mesenchymal cells in monolayer Coculture are likely to
be bidirectional, a possible mode of action could be cross-
talk between cells via gap junctions, which has been observed
in vivo in the lung between transplanted MSCs and resident
epithelial cells [57]. Recently, it has been found that MSCs
could be induced to diﬀerentiate into corneal epithelium [58]
or endothelium [59] in Coculture condition, but not in the
indirect Coculture system where MSCs and endothelial cells
were cultured in separate inserts [59]. More importantly,
BM-MSCs acquired an airway epithelium phenotype when
Cocultured with respiratory epithelial cells and determined
a partial resumption of the chloride secretion defect in CF
epithelia [49]. Although we have not analyzed the correction
of the chloride transport defect in CFBE14o- monolayers by
hAMSCs, based on the work by Wang et al. [49], it can be
anticipated that we should see the same eﬀect on the basic
electrophysiological defect. Furthermore, since only 6–20%
of corrected cells are needed to revert the basic defect in
chloride secretion [60], our data showing that 33–50% of
hAMSCs acquired CFTR expression shed a positive light on
the use of amnion MSCs in the CF treatment.
5. Conclusions
Our data indicate hAMSCs as a novel, promising, readily
accessible, and ethically compatible source of pluripotent
cells that could be used in regenerative medicine. In this res-
pect, hAMSCs present promising features as indicated by
their expression of embryonic stem cell markers such as
SSEA4 and by their diﬀerentiation potential towards meso-
dermal and endodermal lineages.
Although CF is a clinically heterogeneous disease caused
by a defect in the CFTR gene aﬀecting multiple organ sys-
tems, major morbidity and mortality are given by the lung
disease; however, hepatobiliary complications of CF are in-
creasingly common and clinically relevant as the age of pa-
tients increases [61, 62]. This study shows the diﬀerentiative
potential of hAMSCs towards hepatocyte-like cells, which
might be useful in CF, and highlights the need for further
investigations to elucidate the mechanism mediating CFTR
expression in hAMSCs upon cell to-cell interactions.
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